Clinical Trial Update: Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial is evaluating targeted AML1-ETO neoantigen cytotoxic T cells for relapsed or refractory acute myeloid leukemia with the t(8;21) transloca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Translocation

Drugs mentioned

• AML1-ETO targeted neoantigen cytotoxic T cells (CTL)

Snippet

Sponsor: BGI, China | Conditions: AML, t(8;21) | EARLY_Phase 1 | Status: ENROLLING_BY_INVITATION